7210 Wareham Drive, Tampa, FL 33647
June 18, 2025 Following approval of its Plan of Reorganization, WW is on track to exit the court-supervised financial reorganization process as early as next week. “This is a meaningful turning point for WeightWatchers,” said Tara Comonte, CEO of Weight Watchers. “We’ve taken decisive action to significantly strengthen our financial foundation and will emerge with […]
Weight Watchers Reorganization Plan Confirmed Read More »
May 6, 2025 WW management reported first quarter 2025 results today. “We are making progress on our strategic priorities with continued momentum in our Clinical business, while laying the foundation for long-term, sustainable growth,” said Tara Comonte, President and CEO. “As the weight management landscape evolves, we believe our unique combination of science-backed behavioral support,
Weight Watchers Reports Q1 Results Read More »
May 1, 2025 The National Consumers League (NCL) – a leading non-profit fighting fraud in the marketplace – today released a white paper as a blueprint for policy changes to combat the flood of false information circulating online about GLP-1 products and launched an ambitious national anti-disinformation effort called the Weight Truth with the online
April 30, 2025 Herbalife today reported its first quarter 2025 results. The company sells a significant amount of weight management products (meal replacements), and is one the the leading MLM companies selling weight loss products. At $254.4 million, North American sales represented 20.8% of total Herbalife revenues for the quarter. The company had worldwide weight
Herbalife Reports Q1 2025 Results Read More »
April 29, 2025 WW announced a pharmacy integration with Eli Lilly and Company’s LillyDirect® pharmacy provider, Gifthealth. The integration will streamline access to Lilly’s FDA-approved Zepbound® (tirzepatide) single-dose vials for WeightWatchers Clinic members with an on-label prescription from their clinician. As part of WeightWatchers’ holistic approach to weight management, the integration will streamline access to
Weight Watchers Streamlines Member Access to Zepbound® Vials Read More »
April 28, 2025 According to CEO Dan Chard: “This year, we are focused on revitalizing our coach and customer base by supporting them with enhanced tools, data, and new products. Our business focus remains on reestablishing sustainable long-term growth while improving profitability.” First quarter 2025 revenue decreased 33.8% to $115.7 million from $174.7 million for the
Medifast Reports First Quarter Results – Slide Continues Read More »
April 24, 2025 The U.S. Census of Service Industries is performed every 5 years, with the last government survey performed in 2022. Commercial weight loss companies (“diet & reducing centers”) are classified under NAICS code 812191 (other personal services). Establishment and firms data for this industry have just been released (see census.gov). This information is
2022 Census Data Published: Commercial Weight Loss Industry Statistics Read More »
April 24, 2025 Novo Nordisk asked the Food and Drug Administration to approve a pill version of its popular weight loss drug in obesity earlier this year, a spokesperson confirmed. The company first reported in 2023 that the drug, an oral form of semaglutide, succeeded in a Phase 3 trial, helping people on the highest
Novo Nordisk Submits Weight Loss Pill for FDA Approval Read More »
April 22, 2025 Marketdata LLC has just released a new market study: “The U.S. Meal Replacements Market: Retail & MLM Channels”, April 2025. This 77-page report analyses the meal replacements and retail appetite suppressants market in the U.S. The $5.1 billion U.S. meal replacements market has held up fairly well the past few years, despite
$5 Billion U.S. Meal Replacements Market Survives GLP-1s Competition Read More »
April 17, 2025 New research released Thursday morning shows a new, oral GLP-1 pill may be just as beneficial to those with Type 2 diabetes as injectable GLP-1 drugs. Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce hemoglobin A1C levels on average by 1.3-1.6%
Eli Lilly’s New Weight Loss Pill Shows Promise Read More »